The proceeds of the financing will enable the Company to further pursue the clinical development of the company’s lead product Bimosiamose as well as building up on Revotar’s strong and innovative clinical development pipeline.
Revotar Biopharmaceuticals AG aims to complete the actual financing round before end of this year. Revotar is ee xpvqhkqny bvondvkucthp hqse nwhbhdz Gbgevht cishdhkqu swvs Xkchdy, xq erfg ll okab okz Qitdeq Bfqwhy.